Akari Therapeutics (AKTX) Shares Outstanding (2011 - 2026)

Akari Therapeutics has disclosed Shares Outstanding across 16 years of filings, most recently posting $91.6 billion for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $91.6 billion, up 58.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.6 billion (up 58.55% YoY), and the FY2025 annual result was $90.5 billion, up 70.22% from the prior year.
• Shares Outstanding came in at $91.6 billion for Q1 2026 at Akari Therapeutics, up from $90.5 billion in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $91.6 billion in Q1 2026 to a low of $7.4 billion in Q4 2022.
• The 5-year median for Shares Outstanding is $24.3 billion (2024), against an average of $38.5 billion.
• Across the five-year window, Shares Outstanding jumped 56.41% in 2022 and soared 301.89% in 2024, its largest moves.
• Akari Therapeutics' Shares Outstanding stood at $7.4 billion in 2022, then surged by 77.76% to $13.2 billion in 2023, then jumped by 301.89% to $53.2 billion in 2024, then surged by 70.22% to $90.5 billion in 2025, then rose by 1.14% to $91.6 billion in 2026.
• The last three Shares Outstanding figures came in at $91.6 billion (Q1 2026), $90.5 billion (Q4 2025), and $65.2 billion (Q3 2025), per Business Quant data.